Evidence
J Diabetes Complications. 2023 Jun 5;37(8):108525. doi: 10.1016/j.jdiacomp.2023.108525. Online ahead of print.
ABSTRACT
AIMS: To investigate whether soluble CD163 (sCD163) is altered in those with diabetes and various subtypes of complications and non-alcoholic fatty liver disease (NAFLD), and whether it can assess disease complications and severity in people with diabetes.
METHODS: Adults with diabetes (n = 101) were recruited and assessed for the presence of any complications (D+Comps). Liver steatosis presence was determined by ultrasound and liver stiffness measurement (LSM) by transient elastography. Liver pathology other than non-alcoholic steatohepatitis (NASH) was excluded. Plasma sCD163 was measured by ELISA.
RESULTS: sCD163 was higher in D+Comps (n = 59) compared to D-comps (n = 42) in those with microvascular complications (n = 56; 1.3-fold), including a 1.4-fold increase in chronic kidney disease (CKD) (n = 42). sCD163 correlated positively with HbA1c and urinary albumin-creatinine ratio and negatively with HDL-c in D+Comps. sCD163 was increased 1.7-fold in those with advanced NASH fibrosis (LSM ≥ 10.3 kPa, n = 19) compared to those without (LSM < 10.3 kPa, n = 80). The AUC-ROC-curve was 0.64 for sCD163 to detect CKD and 0.74 to detect advanced NASH fibrosis.
CONCLUSIONS: In this study, the elevated circulating sCD163 occurred in people with diabetes who had microvascular complications or advanced NASH fibrosis, suggesting sCD163 may have clinical utility as a biomarker in certain diabetes complications and disease severity in NAFLD.
PMID:37301062 | DOI:10.1016/j.jdiacomp.2023.108525
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Circulating soluble CD163 as a potential biomarker of diabetes complications
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH
- Management of Cardiovascular Risk in the Non-alcoholic Fatty Liver Disease Setting
- Evaluating the incidence of complications among people with diabetes according to age of onset: Findings from the UK Biobank
- Liver fat as a dietary target by Chinese Medical Nutrition Therapy (CMNT) diet for treating type 2 diabetes with non-alcoholic fatty liver disease: study protocol for a randomised controlled trial
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
- Nonalcoholic Fatty Liver Disease and Ethnicity: Lessons Learned from the Arab Population in Israel
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
- Liver fibrosis is associated with left ventricular remodeling: insight into the liver-heart axis
- Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study
- Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome
- EXPRESS: Association of Statins with Onset and Progression of Non-Alcoholic Fatty Liver Disease in Patients with Diabetes
- EXPRESS: Association of Statins with Onset and Progression of Non-Alcoholic Fatty Liver Disease in Patients with Diabetes
- Association between the cardiometabolic index and NAFLD and fibrosis
- Analysis of the therapeutic potential of miR-124 and miR-16 in non-alcoholic fatty liver disease
- Association of physical activity and sports participation with insulin resistance and non-alcoholic fatty liver disease in people with type 1 diabetes
- The evaluation of non-alcoholic fatty liver disease in children with obesity with vibration-controlled transient elastography
- Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- Adipose Tissue Insulin Resistance in South Asian and Nordic Women after Gestational Diabetes Mellitus
- Time trends in liver-related mortality in people with and without diabetes: Results from a population based study
- Spinal cord injury-induced metabolic impairment and steatohepatitis develops in non-obese rats and is exacerbated by premorbid obesity
- Fresh fruit, dried fruit, raw vegetables, and cooked vegetables consumption associated with progression trajectory of type 2 diabetes: a multi-state analysis of a prospective cohort
- Prevalence and outcome of sarcopenia in non-alcoholic fatty liver disease
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- Pro- and anti-inflammatory cytokines are the game-changers in childhood obesity-associated metabolic disorders (diabetes and non-alcoholic fatty liver diseases)
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Glucokinase regulatory protein rs780094 polymorphism is associated with type 2 diabetes mellitus, dyslipidemia, non-alcoholic fatty liver disease, and nephropathy
- Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis
- Early blood glucose control for people with type 2 diabetes is crucial for reducing complications and prolonging life
- Prevalences of Hypertension, Type 2 Diabetes Mellitus, and Cardiovascular Disease in a Cohort of Puerto Ricans with Non-alcoholic Fatty Liver Disease
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Diagnostic performance of the GGT/HDL-C ratio for NAFLD in adults with obesity undergoing bariatric surgery
- Comparative outcomes of trans-arterial radioembolization in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease-induced HCC: a retrospective analysis
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Blood Level of Nitric Oxide Metabolites and Expression of Genes Regulating NO Synthesis in Early Forms of Non-Alcoholic Fatty Liver Disease
- Blood Level of Nitric Oxide Metabolites and Expression of Genes Regulating NO Synthesis in Early Forms of Non-Alcoholic Fatty Liver Disease
- Prevalence of nonalcoholic fatty liver disease and liver cirrhosis in Chinese adults with type 2 diabetes mellitus
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- Diabetes: a review of its pathophysiology, and advanced methods of mitigation
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease
- Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease
- Metabolic dysfunction-associated fatty liver disease and low muscle strength: A comment
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- Hospital admissions for chronic liver diseases: a temporal study in the South Region of Brazil
- Kaempferol efficacy in metabolic diseases: Molecular mechanisms of action in diabetes mellitus, obesity, non-alcoholic fatty liver disease, steatohepatitis, and atherosclerosis
- Influence of nonalcoholic fatty liver disease severity on carotid adventitial vasa vasorum
- Gene-by-Environment Interaction in Non-Alcoholic Fatty Liver Disease and Depression: The Role of Hepatic Transaminases
- Hepatokine ITIH3 protects against hepatic steatosis by downregulating mitochondrial bioenergetics and de novo lipogenesis
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action
- SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
- Gestational diabetes mellitus may predispose to metabolic dysfunction-associated steatotic liver disease
Evidence Blueprint
Circulating soluble CD163 as a potential biomarker of diabetes complications
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Circulating soluble CD163 as a potential biomarker of diabetes complications
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- IL-6 trans-signaling is increased in diabetes, impacted by glucolipotoxicity and associated with liver stiffness and fibrosis in fatty liver disease
- Associations between higher plasma ferritin and hepcidin levels with liver stiffness in patients with type 2 diabetes: An exploratory study
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor
- Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials
- Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease
- A Hospital Based Observational Study to Detect Non-Alcoholic Steatohepatitis by Acoustic Radiation Force Impulse in Individuals with Diabetes Mellitus and Metabolic Syndrome
- Application of artificial intelligence techniques for non-alcoholic fatty liver disease diagnosis: A systematic review (2005-2023)
- Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease
- Non-alcoholic fatty liver disease and incidence of microvascular complications of diabetes in patients with type 2 diabetes: a prospective cohort study
- Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis with liver fibrosis as predictors of new-onset Diabetes Mellitus in People living with HIV: A Longitudinal Cohort Study
- Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH
- Vascular complications and associated comorbidities in newly diagnosed pre-diabetes: is it the tip of the iceberg?
- Liver steatosis as a predictor of incident diabetes in adults: a prospective evaluation in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)
- Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists
- Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis
- Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002-2022)
- Management of Cardiovascular Risk in the Non-alcoholic Fatty Liver Disease Setting
- Evaluating the incidence of complications among people with diabetes according to age of onset: Findings from the UK Biobank
- Diabetes Mellitus among Patients with Non-alcoholic Fatty Liver Disease Visiting the Outpatient Department of Internal Medicine in a Tertiary Care Centre
- Liver fat as a dietary target by Chinese Medical Nutrition Therapy (CMNT) diet for treating type 2 diabetes with non-alcoholic fatty liver disease: study protocol for a randomised controlled trial
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Corrigendum to "The PanGut-study: Evoked potentials following rectal balloon distention, a way of evaluating diabetic autonomic neuropathy in the gut?" [J. Diabetes Complicat., Volume 37, Issue 5, May 2023, 108452]
- Hepatic Fibrosis Evaluated in Patients with Type 2 Diabetes with and without Chronic Kidney Disease
- The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
- Usefulness of two-dimensional shear wave elastography in the assessment of non-alcoholic fatty liver disease in children and adolescents
- Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma
- The Effect of Diabetes Mellitus Type 1 on the Energy Metabolism of Hepatocytes: Multiphoton Microscopy and Fluorescence Lifetime Imaging
- The Role of Platelets in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Therapeutics
- Nonalcoholic Fatty Liver Disease and Ethnicity: Lessons Learned from the Arab Population in Israel
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- A multi-state analysis of disease trajectories and mental health transitions in patients with type 2 diabetes: A population-based retrospective cohort study utilizing health administrative data
- Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach
- Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach
- Liver disease mortality and hospitalisations among people with type 2 diabetes mellitus: A population-based study
- SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
- Myeloid cell iron uptake pathways and paramagnetic rim formation in multiple sclerosis
- Fungal plasma biomarkers in patients admitted for hospital treatment of alcohol use disorder
- Liver fibrosis screening, evaluation pathway, and management in patients with fatty liver
- The epidemiology and characteristics of patients with diabetes with or without NASH: a systematic review
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Identification and multicentric validation of soluble CDCP1 as a robust serological biomarker for risk stratification of NASH in obese Chinese
- Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
- Repeated detection of non-alcoholic fatty liver disease increases the incidence risk of type 2 diabetes in young adults
- Diagnostic Performance of Quantitative Ultrasound Parameters in Non-alcoholic Fatty Liver Disease
- Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials
- AGEs accumulation with vascular complications, glycemic control and metabolic syndrome: A narrative review
- NASH drug treatment development: challenges and lessons
- Risk factors for macro vascular disease in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: A longitudinal cohort study
- A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
- Liver fibrosis is associated with left ventricular remodeling: insight into the liver-heart axis
- ALT Poorly Predicts Nonalcoholic Fatty Liver Disease (NAFLD) and Liver Fibrosis as Determined by Vibration-Controlled Transient Elastography in Adult National Health and Nutrition Examination Survey 2017-2018: ALT Poorly Predicts NAFLD and…
- Liver Stiffness Measurement is Useful in Predicting Type 2 Diabetes Mellitus Among Nonalcohol Fatty Liver Disease Patients
- Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis
- The first human normative ranges and biomarker performance of dimethylguanidino valeric acid isoforms in fatty liver disease
- Metabolic complications of obesity in children and adolescents
- Corrected and republished from: Metabolic associated liver disease
- Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study